[go: up one dir, main page]

DK3788040T3 - Pyridazinoner som parp7-inhibitorer - Google Patents

Pyridazinoner som parp7-inhibitorer Download PDF

Info

Publication number
DK3788040T3
DK3788040T3 DK19723272.1T DK19723272T DK3788040T3 DK 3788040 T3 DK3788040 T3 DK 3788040T3 DK 19723272 T DK19723272 T DK 19723272T DK 3788040 T3 DK3788040 T3 DK 3788040T3
Authority
DK
Denmark
Prior art keywords
pyridazinones
parp7
inhibitors
parp7 inhibitors
Prior art date
Application number
DK19723272.1T
Other languages
English (en)
Inventor
Melissa Marie Vasbinder
Laurie B Schenkel
Kerren Kalai Swinger
Kevin Wayne Kuntz
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Application granted granted Critical
Publication of DK3788040T3 publication Critical patent/DK3788040T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19723272.1T 2018-04-30 2019-04-29 Pyridazinoner som parp7-inhibitorer DK3788040T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862664544P 2018-04-30 2018-04-30
PCT/US2019/029582 WO2019212937A1 (en) 2018-04-30 2019-04-29 Pyridazinones as parp7 inhibitors

Publications (1)

Publication Number Publication Date
DK3788040T3 true DK3788040T3 (da) 2023-05-08

Family

ID=66476851

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19723272.1T DK3788040T3 (da) 2018-04-30 2019-04-29 Pyridazinoner som parp7-inhibitorer

Country Status (36)

Country Link
US (6) US10550105B2 (da)
EP (2) EP4234551A3 (da)
JP (2) JP6942896B2 (da)
KR (1) KR102862474B1 (da)
CN (2) CN112424188B (da)
AR (1) AR121419A1 (da)
AU (2) AU2019262927B2 (da)
BR (1) BR112020022006A2 (da)
CA (1) CA3098585A1 (da)
CL (1) CL2020002821A1 (da)
CO (1) CO2020013599A2 (da)
CR (1) CR20200518A (da)
CY (1) CY1126132T1 (da)
DK (1) DK3788040T3 (da)
EA (1) EA202092590A1 (da)
EC (1) ECSP20069404A (da)
ES (1) ES2949538T3 (da)
FI (1) FI3788040T3 (da)
HR (1) HRP20230458T1 (da)
HU (1) HUE062096T2 (da)
IL (2) IL278116B2 (da)
LT (1) LT3788040T (da)
MA (1) MA52486B1 (da)
MD (1) MD3788040T2 (da)
MX (2) MX2020011465A (da)
PE (1) PE20211382A1 (da)
PH (1) PH12020551760A1 (da)
PL (1) PL3788040T3 (da)
PT (1) PT3788040T (da)
RS (1) RS64283B1 (da)
SG (1) SG11202010183XA (da)
SI (1) SI3788040T1 (da)
SM (1) SMT202300172T1 (da)
TW (2) TWI811353B (da)
WO (1) WO2019212937A1 (da)
ZA (1) ZA202006549B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062096T2 (hu) 2018-04-30 2023-09-28 Ribon Therapeutics Inc Piridazinonok PARP7-inhibitorokként
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
US11512090B2 (en) 2018-06-11 2022-11-29 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
US12054487B2 (en) 2018-09-04 2024-08-06 Contineum Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
EP3941475A4 (en) * 2019-03-20 2023-01-25 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE THEREOF
US12371421B2 (en) 2019-04-29 2025-07-29 Ribon Therapeutics, Inc. Solid forms of a PARP7 inhibitor
MX2022004245A (es) * 2019-10-07 2022-05-26 Pipeline Therapeutics Inc Antagonistas del receptor muscarínico de acetilcolina m1.
WO2021087018A1 (en) * 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
WO2021087025A1 (en) * 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
TW202206422A (zh) * 2020-04-23 2022-02-16 美商普雷辛肯公司 用於ｃｄ７３調節之化合物及方法及其適應症
EP4161923A4 (en) * 2020-06-09 2023-10-11 Relive Therapeutics Inc. Compounds comprising a three ring core as pd-1/pd-l1 blockers
US20230257382A1 (en) * 2020-07-03 2023-08-17 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound and use thereof
WO2022111700A1 (zh) * 2020-11-27 2022-06-02 成都百裕制药股份有限公司 哒嗪酮衍生物及其在医药上的应用
JP7623826B2 (ja) * 2020-12-18 2025-01-29 株式会社 資生堂 Ｔｉｐａｒｐ産生促進剤
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
US20240166664A1 (en) * 2021-02-03 2024-05-23 Shanghai Apeiron Therapeutics Company Limited Triheterocyclic compound, preparation method therefor, and application thereof
AU2022216707B2 (en) * 2021-02-07 2024-05-02 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound, and intermediate thereof, preparation method therefor and use thereof
CN116848114A (zh) * 2021-02-09 2023-10-03 北京加科思新药研发有限公司 用作parp7抑制剂的三环衍生物
TW202245777A (zh) 2021-02-16 2022-12-01 美商律幫治療股份有限公司 Parp7抑制劑之給藥方案
CN115028648B (zh) * 2021-03-03 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2022188889A1 (zh) * 2021-03-12 2022-09-15 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
CA3212319A1 (en) * 2021-03-16 2022-09-22 Hualing XIAO Nitrogen-containing heterocyclic polycyclic compound, preparation method therefor, and application thereof
GB202114315D0 (en) * 2021-10-06 2021-11-17 Duke Street Bio Ltd Pharmaceutical compound
US20240217968A1 (en) 2021-03-31 2024-07-04 Duke Street Bio Limited Pharmaceutical compound
WO2022223022A1 (zh) * 2021-04-23 2022-10-27 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
BR112023023866A2 (pt) * 2021-05-21 2024-02-06 Chengdu Baiyu Pharmaceutical Co Ltd Derivado de piperazina e seu uso na medicina
CN117396485A (zh) * 2021-05-25 2024-01-12 轩竹生物科技股份有限公司 Parp7抑制剂
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023001247A1 (zh) * 2021-07-21 2023-01-26 南京明德新药研发有限公司 哒嗪酮类化合物
CN115677664A (zh) * 2021-07-23 2023-02-03 武汉人福创新药物研发中心有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023011629A1 (zh) * 2021-08-06 2023-02-09 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
CN117377665A (zh) * 2021-08-16 2024-01-09 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
US20240343727A1 (en) * 2021-08-17 2024-10-17 InventisBio Co., Ltd. Pyridazinone or pyridinone compounds, preparation methods and uses thereof
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN116375688B (zh) * 2021-12-23 2025-04-11 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
CN116444497B (zh) * 2022-01-14 2025-06-24 如东凌达生物医药科技有限公司 一类哒嗪酮类化合物、制备及其应用
CN116535395B (zh) * 2022-01-26 2024-07-09 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
WO2023143236A1 (zh) * 2022-01-26 2023-08-03 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
AU2022451580B2 (en) * 2022-04-01 2024-11-07 Novostar Pharmaceuticals, Ltd. Parp7 inhibitor and use thereof
TW202346294A (zh) * 2022-04-21 2023-12-01 大陸商四川海思科製藥有限公司 吡嗪酮衍生物及其在醫藥上的應用
JP2025526003A (ja) * 2022-08-09 2025-08-07 康百達（四川）生物医薬科技有限公司 ピペラジン化合物とｐｄ－１阻害剤またはｐｄ－ｌ１阻害剤との組成物、および腫瘍治療におけるその使用
KR20250044422A (ko) * 2022-08-09 2025-03-31 캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디. 종양 치료를 위한 방사선요법과 병용한 피페라진 화합물의 용도
CN117586263A (zh) * 2022-08-09 2024-02-23 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
CN119731176A (zh) * 2022-08-17 2025-03-28 北京加科思新药研发有限公司 化合物i或其盐的固体形式
GB202213819D0 (en) 2022-09-22 2022-11-09 Duke Street Bio Ltd Pharmaceutical compound
CN115490671B (zh) * 2022-10-21 2024-05-14 水木未来(北京)科技有限公司 Parp7抑制剂及其制备方法
JP2025536416A (ja) * 2022-11-14 2025-11-05 康百達（四川）生物医薬科技有限公司 置換ピペラジン誘導体の結晶およびその調製方法
GB202217888D0 (en) 2022-11-29 2023-01-11 Duke Street Bio Ltd Pharmaceutical compound
WO2024146631A1 (zh) * 2023-01-06 2024-07-11 齐鲁制药有限公司 一种parp7抑制剂的制备方法
CN120917010A (zh) * 2023-01-10 2025-11-07 嘉兴和剂药业有限公司 Parp7抑制剂及其用途
WO2024149234A1 (en) * 2023-01-10 2024-07-18 Angel Pharmaceutical Co., Ltd. Parp7 inhibitors and uses thereof
CN118388414A (zh) * 2023-01-17 2024-07-26 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
TW202508597A (zh) * 2023-08-17 2025-03-01 大陸商康百達（四川）生物醫藥科技有限公司 一種呱嗪衍生物的藥物製劑、其製備方法及其用途
WO2025045134A1 (zh) * 2023-08-29 2025-03-06 康百达（四川）生物医药科技有限公司 一种哌嗪衍生物的制备工艺及其中间体
WO2025087383A1 (zh) * 2023-10-26 2025-05-01 深圳众格生物科技有限公司 作为parp7抑制剂的化合物
WO2025103341A1 (zh) * 2023-11-13 2025-05-22 康百达（四川）生物医药科技有限公司 一种parp7抑制剂联合用药的药物组合及其治疗肿瘤的用途
CN117342983B (zh) * 2023-12-05 2024-02-06 康羽生命科学技术(苏州)有限公司 过乙酰化GalNAc-L96合成方法
WO2025209574A1 (zh) * 2024-04-03 2025-10-09 康百达（四川）生物医药科技有限公司 用于预防或治疗肿瘤的parp7抑制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270233A1 (en) 1997-09-05 1999-03-18 Matsushita Electric Industrial Co., Ltd. Fluorescence polarization method
WO2002082082A2 (en) 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
HU227237B1 (en) * 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
GB0301628D0 (en) 2002-09-19 2003-02-26 Aventis Pharma Inc Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP)
CA2569826C (en) * 2004-06-30 2013-07-16 Janssen Pharmaceutica N.V. Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
JP5335675B2 (ja) 2006-07-25 2013-11-06 セファロン、インク． ピリジジノン誘導体
US8268827B2 (en) 2007-11-15 2012-09-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa. Pyridazinone derivatives as PARP inhibitors
HRP20150139T1 (hr) * 2008-03-27 2015-05-22 Janssen Pharmaceutica N.V. Tetrahidrofenanthridinoni i tetrahidrociklopentakinolinoni kao inhibitori parp i polimerizacije tubulina
ES2608670T3 (es) * 2009-08-17 2017-04-12 Memorial Sloan-Kettering Cancer Center Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
JP2016512239A (ja) * 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
WO2016116602A1 (en) * 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
CN106749261A (zh) * 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
AU2018334290A1 (en) * 2017-09-18 2020-04-02 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
GB201717080D0 (en) 2017-10-18 2017-11-29 Syngenta Participations Ag Chemical process
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
HUE062096T2 (hu) 2018-04-30 2023-09-28 Ribon Therapeutics Inc Piridazinonok PARP7-inhibitorokként
US12371421B2 (en) 2019-04-29 2025-07-29 Ribon Therapeutics, Inc. Solid forms of a PARP7 inhibitor
WO2021087018A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
WO2021087025A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors

Also Published As

Publication number Publication date
KR20210014108A (ko) 2021-02-08
PL3788040T3 (pl) 2023-08-07
BR112020022006A2 (pt) 2021-01-26
IL278116B2 (en) 2024-04-01
TW202014416A (zh) 2020-04-16
IL308983A (en) 2024-01-01
US20210024502A1 (en) 2021-01-28
CN112424188B (zh) 2025-06-27
PH12020551760A1 (en) 2021-06-28
MD3788040T2 (ro) 2023-10-31
AR121419A1 (es) 2022-06-08
AU2019262927B2 (en) 2023-11-02
US20230192664A1 (en) 2023-06-22
TWI811353B (zh) 2023-08-11
FI3788040T3 (fi) 2023-06-13
SMT202300172T1 (it) 2023-09-06
PT3788040T (pt) 2023-07-12
ECSP20069404A (es) 2021-01-29
US11566020B1 (en) 2023-01-31
HUE062096T2 (hu) 2023-09-28
AU2024200566A1 (en) 2024-02-15
US10870641B2 (en) 2020-12-22
SG11202010183XA (en) 2020-11-27
US20250034120A1 (en) 2025-01-30
ES2949538T3 (es) 2023-09-29
EP4234551A2 (en) 2023-08-30
MX2023005804A (es) 2023-05-29
IL278116B1 (en) 2023-12-01
KR102862474B1 (ko) 2025-09-24
CO2020013599A2 (es) 2020-12-21
JP6942896B2 (ja) 2021-09-29
EA202092590A1 (ru) 2021-04-08
PE20211382A1 (es) 2021-07-27
IL308983B1 (en) 2025-06-01
CR20200518A (es) 2021-03-22
CN120987912A (zh) 2025-11-21
MA52486A (fr) 2021-03-10
SI3788040T1 (sl) 2023-07-31
JP7518049B2 (ja) 2024-07-17
LT3788040T (lt) 2023-06-26
MX2020011465A (es) 2020-12-07
JP2021523104A (ja) 2021-09-02
IL308983B2 (en) 2025-10-01
US11014913B2 (en) 2021-05-25
HRP20230458T1 (hr) 2023-07-21
CY1126132T1 (el) 2023-11-15
US10550105B2 (en) 2020-02-04
TW202344505A (zh) 2023-11-16
EP3788040A1 (en) 2021-03-10
ZA202006549B (en) 2025-06-25
MA52486B1 (fr) 2023-04-28
US20190330194A1 (en) 2019-10-31
CL2020002821A1 (es) 2021-02-19
WO2019212937A1 (en) 2019-11-07
IL278116A (en) 2020-11-30
JP2022017221A (ja) 2022-01-25
EP4234551A3 (en) 2023-10-11
US20200123134A1 (en) 2020-04-23
CA3098585A1 (en) 2019-11-07
TWI877697B (zh) 2025-03-21
CN112424188A (zh) 2021-02-26
RS64283B1 (sr) 2023-07-31
EP3788040B1 (en) 2023-04-12
AU2019262927A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
DK3788040T3 (da) Pyridazinoner som parp7-inhibitorer
IL283639A (en) Kif18a inhibitors
DK3999506T3 (da) Parp1-hæmmere
EP4007752C0 (en) Kif18a inhibitors
MA54550A (fr) Inhibiteurs de kif18a
EP3898616C0 (en) HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
EP3898592C0 (en) HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
IL269196A (en) Novel inhibitors
EP4007753C0 (en) Kif18a inhibitors
DK3697785T3 (da) Imidazo-pyridine forbindelser som pad-inhibitorer
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
DK3704120T3 (da) Heterocykliske forbindelser som prmt5-inhibitorer
DK3684767T3 (da) Heterocykliske forbindelser som pad-inhibitorer
MA52812A (fr) Inhibiteurs de sarm1
DK3580220T3 (da) Aminotriazolpyridiner som kinasehæmmere
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
IL304348A (en) Cd73 inhibitors
DK3571192T3 (da) Jak1-selektive inhibitorer
EP3801499A4 (en) INHIBITORS OF SARM1
MA52813A (fr) Inhibiteurs de sarm1
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
DK3728207T3 (da) Quinazolinoner som parp14-inhibitorer
EP3804707A4 (en) KINASE INHIBITOR
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
EP3817736A4 (en) PIKFYVE INHIBITORS